Mallinckrodt Sues Baxter to Block Copies of Ofirmev Drug

Mallinckrodt said a generic version of injectable acetaminophen proposed by Baxter International’s Baxter Healthcare unit infringes five patents for Ofirmev, used to reduce pain and fever.

• Mallinckrodt is seeking a court order blocking copies until the patents have expired, and to collect cash compensation if copies are made before then, according to complaint filed Friday in federal court in Wilmington, Delaware
• Patents expire in December 2021, November 2028, May 2029 and March 2032, according to supplemental filing
• Mallinckrodt owns four of the patents and is the exclusive sub-licensee of a fifth, complaint says
  • Closely held New Pharmatop, a co-plaintiff, ...